

BioCentury

THE BERNSTEIN REPORT ON BIOBUSINESS™

Article Reprint • Page 1 of 1

CLINICAL NEWS

CLINICAL STATUS

Bionor Pharma ASA (OSE:BIONOR), Oslo, Norway

Product: Vacc-4x

Business: Infectious

Molecular target: NA

Description: Therapeutic peptide composed of 4 modified synthetic peptides that correspond to a conserved domain of the p24 protein

Indication: Vaccinate against HIV/AIDS

Endpoint: NA

Status: Phase I/II start

Milestone: Start Phase I/II (4Q11); Phase I/II data (1H13)

By next quarter, Bionor will begin a German Phase I/II trial to compare its Vacc-4x in combination with Revlimid lenalidomide vs. Vacc-4x alone in HIV-infected patients on antiretroviral therapy (ART) with a CD4 T cell count of 250-400 cells/mL. The open-label, dose-escalation portion will evaluate 5, 10 and 20 mg doses of Revlimid to determine the maximum tolerated dose (MTD). In the double-blind, placebo-controlled portion, 24 patients will receive Vacc-4x plus the MTD of Revlimid or Vacc-4x alone for 26 weeks.

Revlimid, a thalidomide analog from Celgene Corp. (NASDAQ: CELG, Summit, N.J.), is marketed in the EU and U.S. in combination with dexamethasone to treat multiple myeloma (MM) and in the U.S. to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS). Bionor and Celgene will jointly fund the trial.

BioCentury®
THE BERNSTEIN REPORT ON BIOBUSINESS

PO Box 1246
San Carlos CA 94070-1246
Voice: 650-595-5333
Fax: 650-595-5589
www.biocentury.com

DAVID FLORES
President & CEO

KAREN BERNSTEIN, Ph.D.
Chairman & Editor-in-Chief

BioCentury®, The BioCentury 100, and The Clear Route are trademarks of BIOCENTURY PUBLICATIONS INC. All contents © Copyright 2011, BIOCENTURY PUBLICATIONS INC. ALL RIGHTS RESERVED. No part of this publication may be reproduced, photocopied or reproduced in any form, retransmitted, or stored in a retrieval system without prior written consent of the publisher.

The contents of this publication are gathered from sources believed to be reliable, but in any case are not warranted by the publisher for a particular use or purpose. Also, the content and opinions herein may change without notice and do not constitute investment advice.